Efficacy News and Research

RSS

FDA’s proposed food label not as effective as warning-style designs

The efficacy of front-of-package labels varies; Multi-High-In shows superior results in promoting healthier food choices compared to FDA's Nutrition Info Box.

27 Mar 2026

New initiative aims to scale individualized therapies for rare diseases

Critical Path Institute (C-Path) today announced the launch of One to Millions, a global, multi-stakeholder public-private initiative to enable scalable development of advanced therapies for highly individualized conditions.

26 Mar 2026

Microfluidic chips enable realistic modeling of tumor immune environments

The challenge is that the tumor immune microenvironment is not a static backdrop but a constantly shifting ecosystem shaped by cancer cells, immune cells, stromal cells, cytokines, and physical barriers.

26 Mar 2026

Novel bacteriophage offers a promising biocontrol solution against foodborne Salmonella

Researchers from China have identified a novel bacteriophage that offers a highly promising "green" biocontrol solution against foodborne Salmonella.

26 Mar 2026

Experts establish standardized protocols for pediatric recurrent wheezing diagnosis

Recurrent wheezing, a respiratory disorder, is caused by the narrowing of the airways, mainly affecting children aged less than 5 years.

26 Mar 2026

Immunotherapy plus chemotherapy improves outcomes in stage III dMMR colon cancer

A new study from researchers at the Alliance for Clinical Trials in Oncology (Alliance) shows that patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq®) was added to standard chemotherapy after surgery.

25 Mar 2026

Experts propose trial to evaluate obesity medications for cancer prevention

In new research to be presented at this year's European Congress on Obesity (ECO2026) in Istanbul, Turkey (12-15 May), a global panel of 21 obesity and cancer experts suggest that to test the potential efficacy of the new generation of obesity drugs such as semaglutide and tirzepatide in preventing obesity-related cancer (ORC), a trial of the drugs for some 5,000 participants at high risk of cancer due to their having a cancer pre-cursor condition will provide the required answers.

25 Mar 2026

Blood pressure drug boosts effectiveness of cancer therapy

In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found that the FDA-approved blood pressure drug telmisartan can significantly enhance the cancer-killing activity of the targeted therapy olaparib, potentially expanding its use to many more patients.

25 Mar 2026

Passion fruit molecule may help prevent Alzheimer’s disease progression

Four years ago, a research group at the University of Oslo made what would turn out to be a major discovery.

25 Mar 2026

Can collagen supplements really improve your skin?

Investigating collagen peptides, this review explores their role in skin aging, assessing clinical evidence and the mechanisms behind their potential benefits.

25 Mar 2026

Primerdesign partners with Origin Sciences to create novel rectal mucosal extraction workflow

Primerdesign (part of the Novacyt Group), a company focused on the design, manufacture, validation and supply of nucleic acid extraction and real-time PCR kits, and Origin Sciences (Origin), a company pioneering the detection and diagnosis of gastrointestinal (GI) disease through an unprecedented focus on a unique biospecimen: rectal mucus; today announced a strategic partnership to create a new protocol that optimizes DNA extraction from novel rectal mucosal samples.

From Primerdesign 25 Mar 2026

New insights into acupoint sensitization in disease diagnosis and therapy

In both traditional acupuncture theory and modern medical experience, acupoints are central to therapeutic outcomes, yet their biological nature has remained controversial.

24 Mar 2026

Wholegrain rye changes gut bacteria and lowers inflammation in obesity trial

In a 12-week randomized trial, replacing refined wheat with wholegrain rye in a calorie-restricted diet did not produce greater weight loss in adults with overweight or obesity. Wholegrain rye did, however, lower C-reactive protein and alter gut microbiota and short-chain fatty acids in ways that may have positive cardiometabolic implications.

24 Mar 2026

Home-based program reduces falls among stroke survivors by one-third

New Australian research has shown that a tailored, home-based program can dramatically cut the number of falls, one of the most dangerous risks faced by survivors of stroke.

24 Mar 2026

Palmatine improved fatty liver markers in a preclinical type 2 diabetes study

Researchers used a bioinformatics-plus-rat-model approach to investigate how palmatine may help treat T2DM-associated MASLD, identifying five core targets: ADRB2, BCL3, EGR1, FOS, and MAP3K8. In rats, palmatine improved liver injury, inflammation, oxidative stress, glycolipid metabolism, steatosis, and fibrosis, while reducing apoptosis-related signaling, providing a preclinical foundation for further therapeutic study.

23 Mar 2026

Scientists turn red blood cells into long-lasting drug and imaging carriers in mice

A new preclinical study shows that red blood cells can be tagged in vivo and used as long-lasting carriers for imaging agents and therapies, opening a new route for safer drug delivery and vascular imaging.

23 Mar 2026

How parents shape kids’ fruit and vegetable habits

This study presents a new questionnaire to assess parenting practices influencing children's fruit and vegetable intake, validated across diverse populations.

23 Mar 2026

Digital decision support tool improves outcomes in colorectal surgery

Research published in The Lancet Gastroenterology & Hepatology provides robust evidence for the use of a digital visualization and decision support tool in colorectal (bowel) surgery.

23 Mar 2026

Oral semaglutide fails to slow early Alzheimer’s decline in two phase 3 trials

Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in people with early symptomatic, amyloid-positive Alzheimer’s disease. Semaglutide was generally consistent with its known safety profile and showed some biomarker changes, but these did not translate into clinical benefit.

22 Mar 2026